DA
IBRX icon

Dillon & Associates’s ImmunityBio IBRX Stock Holding History

Dillon & Associates’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Hold
23,800
– – 0.03% 78
2026
Q1 		$190K Sell
23,800
-2,000
-8% -$13.7K 0.03% 75
2025
Q4 		$52K Hold
25,800
– – 0.01% 77
2025
Q3 		$52K Hold
25,800
– – 0.01% 76
2025
Q2 		$77K Buy
+25,800
New +$69.4K 0.01% 77

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dillon & Associates's IBRX Position: Q2 2026 in Review

Dillon & Associates held its ImmunityBio (IBRX) position steady in Q2 2026 at 23,800 shares worth $214K. The position accounts for 0.03% of the portfolio, ranked #78.

Dillon & Associates first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Dillon & Associates held 23,800 shares of ImmunityBio worth $214K as of Q2 2026.
  • Dillon & Associates left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up 0.03% of Dillon & Associates's portfolio in Q2 2026, its #78 holding.
  • Dillon & Associates first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Dillon & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.